Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Scientists identify novel gene mutation that causes glioblastoma

Scientists identify novel gene mutation that causes glioblastoma

Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC

Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC

Idera third quarter net loss increases to $5.5 million

Idera third quarter net loss increases to $5.5 million

JPO issues new patent for Genprex's lead lung cancer candidate

JPO issues new patent for Genprex's lead lung cancer candidate

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

USPTO awards patent for Convergen LifeSciences' CNVN202 to treat lung cancer

USPTO awards patent for Convergen LifeSciences' CNVN202 to treat lung cancer

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Erlotinib phase III study results on lung cancer presented at IASLC conference

Erlotinib phase III study results on lung cancer presented at IASLC conference

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Syndax to present entinostat data against cancer at AACR meeting

Syndax to present entinostat data against cancer at AACR meeting

Idera reports $6.0 million net loss for fourth quarter 2010

Idera reports $6.0 million net loss for fourth quarter 2010